Tagraxofusp-ERZS Drug Asset Due Diligence Report 2026

This Tagraxofusp-ERZS Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tagraxofusp-ERZS can convert its Fusion protein profile and CD123 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tagraxofusp-ERZS (query alias: tagraxofusp)
Modality / target	Fusion protein; CD123; CD123 inhibitors
Highest global status	Approved
Originator	Texas A&M University
Active developers	Stemline Therapeutics, Inc., Menarini Von Heyden GmbH, The University of Texas MD Anderson Cancer Center

The MCP disease footprint includes Blastic Plasmacytoid Dendritic Cell Neoplasm, CD123 Positive Acute Myeloid Leukemia, Acute Myeloid Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07007052	Phase 2	Recruiting	33	Proportion of participants who achieve a cCR (CR or Cri or CRc) after 3 TAGVEN cycles
NCT07148180	Phase 1/2	Recruiting	31	Recommended phase II dose (RP2D) of tagraxofusp in combination with fixed dose of Azacitidine and Venetoclax [Phase I]
NCT06561152	Phase 1/2	Recruiting	20	Recommended Phase 2 dose

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN.

Phase 2; n=19; evaluation: Positive. Reported fields: AE = The most common any grade adverse events (AE) were edema (n = 13) and fatigue (n = 11). There were 2 grade 5 AE (progression, respiratory failure). ; AE = The most common any grade adverse events (AE) were edema (n = 13) and fatigue (n = 11). There were 2 grade 5 AE (progression, respiratory failure).

A PHASE II TRIAL OF TAGRAXOFUSP, HYPER-CVAD, AND VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED OR RELAPSED/REFRACTORY BPDCN

Phase 2; n=19; evaluation: Positive. Reported fields: Capillary Leak Syndrome = Any grade capillary leak syndrome (CLS) was seen in 2 pts (10%); both grade 3 ; Capillary Leak Syndrome = Any grade capillary leak syndrome (CLS) was seen in 2 pts (10%); both grade 3

FAVORABLE HEALTHCARE RESOURCE UTILIZATION (HCRU) WITH TAGRAXOFUSP (TAG) VS VENETOCLAX (VEN) IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): RESULTS OF A REAL-WORLD (RW) ANALYSIS

Not Applicable; n=94; evaluation: Positive. Reported fields: ER visit(2-6 month postindex) = 27.0 % ; ER visit(2-6 month postindex) = 24.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tagraxofusp-ERZS addresses Blastic Plasmacytoid Dendritic Cell Neoplasm, CD123 Positive Acute Myeloid Leukemia, Acute Myeloid Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-03-29	Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZONRIS® (Tagraxofusp) in Japan	Approved	Financial terms not disclosed
2021-03-18	Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZONRIS® (Tagraxofusp) in Japan	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO